Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
TLK-286: a novel glutathione S-transferase-activated prodrug
In 2009, Novo Nordisk's Liraglutide (Victoza) was approved by the EMA and in January 2010 by the FDA for the treatment of type 2 diabetes
Synopsis NRF2 utilizes the CBP/p300 coactivator to drive glutathione synthesis, yet this functional interaction is not required to support non-small cell lung cancer proliferation
Fietta, P
UA, as a single therapeutic approach, may not fully address the complexities of neurodegenerative diseases and may need to be combined with other treatment methods
The truth, of course, falls somewhere in the middle
US$ 29.07
US$ 28.12
US$ 20.19
US$ 22.21
US$ 25.62
US$ 25.52
US$ 24.62
